more thoughts from The oNiOnHEAd Here are some

New Post Public Reply Private Reply Replies (0) Message Board
crazyjogger925
746
more thoughts from The oNiOnHEAd




Here are some more notes - some paraphrased, and some quotes, without the marks, not very detailed - there are surely some errors. Most of the following deals with the Q&A session.


There will be a press release covering the study endpoints. Nader says they want to get all the efficacy data. All physicians involved in the study will contributors to a paper published in a major journal.

A. Interim analysis of 50 patients?
Nader - when he said 50, he was hoping they would do 50, but "slapped around by our regulatory team more than I can count." (more on this that I didn't get - something about a higher number)

Question regarding MS:
Nader - Trying hard to get an MS study going. A mountain of people fighting the company.

Question: Why did a drug like Remdesivir get approved by FDA, but leronlimab, not?
Nader: I wake up every morning very early, very anxious... my team has been spectacular... I have to say when you have 2000 drug companies saying that they got their miracle drug...(apparent there are too many companies wanting the FDA's attention)... We are trying so hard to get the results to the FDA. You just heard fantastic results... I have to defend FDA in this... They relaxed CD12 for us, twice...

Questioner doesn't give up, asks a follow up question, can Cytodyn approach the President.
Nader, FDA has not shorted us. They immediately waived the waiting time, FDA has not given these considerations to anyone else.

FDA has NOT seen any of the results. Mexico changed direction and wanted to do combo therapy, we are not into that.

Q. With all wonderful results, what is plan for federal funding?
A. Nader - Told the team not to work on that because it takes so much resources. When we hear from FDA that we have approval, all those doors will open - we've chosen this different path.

Q. Do you have a real good contact to converse with at FDA. If so, do you share results?
A. Nader - the way FDA works is very solid, with clear rules and regulations. Our contact person is a lady who communicates with Amerex, X-CEO who formerly worked with/for FDA. Everything is much more solid (formal).

Q. How rapidly did patients in CD10 clear the virus compared to control group?
A. Nader - the score that was used to determine endpoint, Day 3, and secondary endpoint. Everyone must wait until we have regulatory support to see the topline results.

Q. Any studies being done for children with lymphoma.
A. Dr. We've screened several... but no efficacy results are available. Nader - we haven't done any pediatric studies.

Q. Are separate patents required for separate indications?
A. Dr. Kelly - working with legal team for that?

Nader - Composition material Patent gives us the right to not have anybody use the product for any other indication.

We have exclusive right of 12 years because patent is for biologic.

Q1. Regeneron change primary endpoint. Can Cytodyn do that in the context of having such fabulous SAE numbers - is a consideration?

Nader - We didn't do phase 3, we did phase 2 (proof of concept). When you have a phase 2 and strong results, if indication is unmet medical need, you can get breakthrough designation, which Cytodyne believes Covid-19 qualifies. Secondary endpoint is as important as primary endpoint

Dr. Kelly - no reason to change endpoint, now, many people are using SAE as endpoint.

Q2. Number of vials dropping - opportunity for production that we don't know about. 600 - 700 vials expected
Nader - Samsung got booked, couldn't make what Cytodyne wanted. Samsung CEO very close to me (Nader), did the 1 million et al vials even though they were booked. 2021 - Samsung will do their best. Another facility, AGC will also be working on it - maybe 100k vials but trying to get more, Nader will let everyone know. With FDA approval, funding not a problem (ie. to get more production).

Q1. Question for doctors
Does this decrease or eliminate viral load by Day 14?

Q2. If there WAS a phase 3 trial, what would it look like, how long would it take? Nader not about to eleborate?

Q3. Cytokine Storm related to influenza?

Q4. Can decrease tumor necrosis factor?

Dr. ? - leronlimab restores CD8, which affects viral load. Exploring cytokine storm related to influenza


Q. Regarding 28 million - are there conditions to financing related to the current trials.
? - no milestones tied to funding, closed yesterday, expected today.

Q. Heard about positive results, but did not talk about the magnitude.
A. Nader - Magnitude will be in topline report.
We have very positive results in Day 3, 7 and 14.
Believe it will be better than Remdesivir. Let's see what the FDA will say.

Q1. Heard or seen Trump mentioned he's looking forward to a therapeutic (shot). Any idea of referring to leronlimab?
Nader - I have no idea. Scott, are we the only ones? Scott - most are IV infusions. We are the only one's with SubQ injections.

Q2. Several weeks ago - mentioned papers out there with positive peer review.
Nader 3 papers now (names), hoping to be out next week. No idea why taking so long.

Final Q. Wants to elab on earlier question. PR on primary and secondary endpoints going to be released?
Nader - next week we report on CD12 safety. CD10 top line report hope to be released in 10 days. Most doctors and patients in that paper.

Nader - no one dares go after (other bio-pharmas attempt to treat certain class of patients) (implying only Cytodyn does)

CD12 is trial based on 60 major INDs, very happy to announce those results. Cancer trial is going forward. Going to have a meeting with FDA - will ask for guidance on monotherapy and combo therapy.

Someone just paid us $10 per share. We just bought ourselves a lot of time and a lot of money. We don't choose to merely go on, but want shareholders to get fruits of hard work.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 264

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 207

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 317

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 175

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 367

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 272

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 414

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 217

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 238

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 121

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading

Top 5 Most Recently Viewed Articles

Van Horn Automotive Group Partners for Successful Dealership Sale

Updated Category News Views 928

Van Horn Automotive Group Sells Ford and Chevrolet Dealerships Performance Brokerage Services, recognized as a leader in dealership buy-sell transactions, has announced the acquisition of Van Horn Ford and Van Horn Chevrolet from Van Horn Automotive Group, marking an important transition for the dealerships. The new owners, Yelena and Alex Tovstanovsky of Sky Auto Mall,...

Continue Reading
G2 Goldfields Unveils Exciting Drilling Results at OKO

Updated Category News Views 136

G2 Goldfields Expands Mineral Resources at OKO G2 Goldfields Inc. (“G2”) (TSX: GTWO; OTCQX: GUYGF) has some exciting updates to share about its exploration activities at the vast 27,719-acre OKO-AREMU gold project. The company recently provided a significant update on their Mineral Resource Estimate (MRE), which now shows a remarkable total of 922,000 ounces of gold...

Continue Reading
Ecolectro Secures $10.5M Series A Funding for Green Hydrogen

Updated Category News Views 425

Ecolectro's Game-Changing Series A Funding Round Ecolectro has successfully completed a significant funding round, securing $10.5 million to enhance its innovative green hydrogen technology. The funding, led by Toyota Ventures, will enable Ecolectro to further develop its fully integrated and scalable electrolyzers, crucial for producing green hydrogen efficiently and...

Continue Reading
CEI Vision Partners Faces Data Breach Investigation: What to Know

Updated Category News Views 233

CEI Vision Partners Confronts Serious Data Breach Investigation In recent news, CEI Vision Partners, a prominent network of over 300 ophthalmologists and 700 optometrists, finds itself at the center of a significant data breach investigation. The investigation, led by the firm Schubert Jonckheer & Kolbe LLP, aims to uncover the details surrounding unauthorized access to...

Continue Reading
New Ethical AI Tools and Books Revolutionizing College Essays

Updated Category News Views 272

Innovative Solutions for College Essay Writing In light of recent prohibitions against artificial intelligence writing tools at major universities, students are navigating the challenges of crafting their college essays with greater scrutiny. College Essay Advisors has responded to this shift by introducing College EssAI, an innovative ethical AI platform designed to...

Continue Reading